HC Wainwright Cuts Agenus (NASDAQ:AGEN) Price Target to $7.00

Agenus (NASDAQ:AGEN) had its price target decreased by HC Wainwright from $8.00 to $7.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the biotechnology company’s stock.

AGEN has been the subject of several other research reports. B. Riley reduced their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $8.00 in a research note on Friday, July 19th. Baird R W cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. William Blair cut shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. Finally, StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Agenus has a consensus rating of “Hold” and a consensus price target of $10.00.

Agenus Stock Performance

AGEN stock opened at $2.72 on Tuesday. Agenus has a one year low of $2.58 and a one year high of $19.69. The stock has a market capitalization of $63.81 million, a PE ratio of -0.24 and a beta of 1.39. The company has a fifty day moving average of $4.70 and a 200-day moving average of $8.70.

Hedge Funds Weigh In On Agenus

Several hedge funds have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. raised its position in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after buying an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Agenus by 1,959.9% in the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after buying an additional 720,629 shares during the last quarter. State Street Corp raised its position in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after buying an additional 9,731 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 84,477 shares during the last quarter. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.